Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5BVE

Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase

Summary for 5BVE
Entry DOI10.2210/pdb5bve/pdb
Related5BVD 5BVF
DescriptorMitogen-activated protein kinase 1, 2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-8-[2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one, SULFATE ION, ... (4 entities in total)
Functional Keywordsinhibitor, kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm, cytoskeleton, spindle : P28482
Total number of polymer chains1
Total formula weight42333.85
Authors
Ma, X.,Steven, S. (deposition date: 2015-06-05, release date: 2015-09-09, Last modification date: 2023-09-27)
Primary citationBagdanoff, J.T.,Jain, R.,Han, W.,Zhu, S.,Madiera, A.M.,Lee, P.S.,Ma, X.,Poon, D.
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.
Bioorg.Med.Chem.Lett., 25:3788-3792, 2015
Cited by
PubMed Abstract: A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase. The role of fluorination in mitigating microsomal clearance was systematically explored. Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.
PubMed: 26259804
DOI: 10.1016/j.bmcl.2015.07.091
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon